| Presentations |
| ACASI Questionnaire Schedule - Oral | 2010-Aug-16 | 205.5 KB |
| Administering Behavioral CRFs | 2010-Aug-16 | 1.25 MB |
| Contraception Counseling Considerations | 2010-Aug-16 | 2.33 MB |
| Data Management Considerations | 2010-Aug-16 | 1.38 MB |
| DataFax Overview and CRF Completion | 2010-Aug-16 | 842.5 KB |
| Follow-up Visit Scheduling and Visit Coding | 2010-Aug-16 | 1.28 MB |
| General Interviewing Techniques | 2010-Aug-16 | 875.5 KB |
| HIV Counseling and Testing | 2010-Aug-16 | 223 KB |
| Informed Consent Process: Key Considerations | 2010-Aug-16 | 2.34 MB |
| Laboratory Training | 2010-Aug-16 | 256.5 KB |
| More on Adverse Events | 2010-Aug-30 | 166.5 KB |
| Overview of Tenofovir’s Anticipated Adverse Events and Resistance Concerns | 2010-Aug-17 | 1.3 MB |
| Participant Accrual Plans | 2010-Aug-16 | 451 KB |
| Participant Retention Plans | 2010-Aug-16 | 437 KB |
| Participant Safety and Monitoring | 2010-Aug-16 | 4.13 MB |
| Randomization Overview | 2010-Aug-16 | 1.76 MB |
| Rounding and Lab Results | 2010-Aug-16 | 212 KB |
| Selected Clinical Considerations | 2010-Aug-16 | 1.13 MB |
| Social Harms:Expectations for Site Planning and Preparation | 2010-Aug-16 | 181.5 KB |
| Specimen Labeling and Preparation for Entry into LDMS | 2010-Aug-16 | 651.5 KB |
| Study Product Adherence Counseling At Enrollment | 2010-Aug-16 | 3.98 MB |
| Study Product Adherence Counseling At Follow-up Visits | 2010-Aug-16 | 180.5 KB |
| Study Product Return Re-Supply and Re-Issue | 2010-Aug-16 | 4.37 MB |
| Syphilis in VOICE | 2010-Aug-16 | 281.5 KB |
| Use of Safety Monitoring Flow Sheets | 2010-Aug-16 | 1001.5 KB |
